Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 12, 2024
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter 2024 financial results and provided a business update.
Read more at globenewswire.com
